Prelude Therapeutics Stock Quote PRLD - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.97

Bid

1.98

Ask

1.99

Volume

92,869

1.92 Day's Range 2.05

1.66 52 Week Range 6.80

Market Cap

108.398M

Previous Close

2.00

Open

1.97

Last Trade

209

1.97

Last Trade Time

15:53:32

Financial Volume

$ 185,419

VWAP

1.9966

Average Volume (3m)

293,462

Shares Outstanding

55,024,470

Dividend Yield

PE Ratio

-0.87

Earnings Per Share (EPS)

-2.21

Revenue

Net Profit

-121.83M

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.preludetx.com

Headquarters

Wilmington, Delaware, USA

Founded

Prelude Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRLD. The last closing price for Prelude Therapeutics was $2. Over the last year, Prelude Therapeutics shares have traded in a share price range of $ 1.66 to $ 6.80.

Prelude Therapeutics currently has 55,024,470 shares outstanding. The market capitalization of Prelude Therapeutics is $110.05 million. Prelude Therapeutics has a price to earnings ratio (PE ratio) of -0.87.

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...

Form 8-K - Current report

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.13	-6.19047619048	2.1	2.16	1.86	168838	2.00430217	CS
4	-2.93	-59.7959183673	4.9	5.53	1.86	439999	2.73110439	CS
12	-2.63	-57.1739130435	4.6	6.8	1.86	293462	4.06366699	CS
26	-2.75	-58.2627118644	4.72	6.8	1.86	166320	4.05096919	CS
52	-0.85	-30.1418439716	2.82	6.8	1.66	154487	3.64529011	CS
156	-22.63	-91.9918699187	24.6	24.6	1.66	177689	7.80555748	CS
260	-23.79	-92.352484472	25.76	95.375	1.66	191143	19.01249551	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	$ 0.00 (0.00%)	0
AACGATA Creativity Global	$ 0.00 (0.00%)	0
AALAmerican Airlines Group Inc	$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	$ 0.00 (0.00%)	0
AACGATA Creativity Global	$ 0.00 (0.00%)	0
AALAmerican Airlines Group Inc	$ 0.00 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.00 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 0.00 (0.00%)	0
AADIAadi Bioscience Inc	$ 0.00 (0.00%)	0
AACGATA Creativity Global	$ 0.00 (0.00%)	0